Ir para o conteúdo principal

Race Oncology (ASX: RAC) — Perfil da empresa, notícias e dados financeiros

Logo de Race Oncology
RAC Race Oncology
Race Oncology primary media
Perfil da empresa

Race Oncology

Race Oncology is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs in cancer care and cardiovascular protection. The company develops targeted small molecule therapeutics designed to act both as potent inhibitors of fat mass and obesity-associated RNA demethylase enzymes and as cardioprotective oncological agents. Its clinical and preclinical research programs target hematological cancers, including acute myeloid leukemia, as well as solid tumors such as breast cancer and melanoma. Through reformulation and combination treatment strategies, the company aims to reduce chemotherapy-induced cardiac damage while delivering improved therapeutic outcomes across oncology indications.

Resumo

Public AUParticipação acionária
2011Ano de fundação
11–50Funcionários
Sydney, AustraliaSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Race Oncology

  • Targeted Oncology Therapeutics: Development of small molecule chemotherapeutic agents targeting m6A RNA demethylase enzymes, specifically fat mass and obesity-associated proteins, to disrupt cancer cell survival mechanisms in relapsed or refractory hematological malignancies and advanced solid tumors.
  • Cardioprotective Chemotherapy Formulations: Research and formulation of novel intravenous drug candidates designed to prevent anthracycline-induced cardiotoxicity in cancer patients receiving standard chemotherapy regimens, enabling safer delivery of potent antineoplastic treatments without sacrificing oncological efficacy.
  • Acute Myeloid Leukemia Programs: Clinical trial programs evaluating targeted small molecule monotherapies and combination regimens for adult and pediatric patients diagnosed with relapsed or refractory acute myeloid leukemia and extramedullary hematological malignancies.
  • Solid Tumor Combination Therapies: Preclinical and early-phase clinical evaluation of targeted oncological molecules combined with standard chemotherapeutics, immunotherapy agents, and targeted inhibitors across solid tumor indications including triple-negative breast cancer and metastatic melanoma.
  • Proprietary Pharmaceutical Reformulation: Development of optimized drug delivery systems, oral dosage forms, and improved parenteral formulations aimed at enhancing bioavailability, reducing administration complexity, and expanding intellectual property protection across global healthcare markets.
  • Strategic Research Collaborations: Collaborative research partnerships with international academic institutions, oncology clinical networks, and contract development and manufacturing organizations to advance translational oncology studies, biomarker discovery, and international clinical trial execution.

equipe executiva do Race Oncology

  • Peter Michael SmithExecutive Chairman
  • Daniel TillettCEO, MD & Director
  • Brendan BrownChief Financial Officer
  • Sophia MoscovisVice President of Operations & Strategy
  • Jose L. IglesiasChief Medical Officer
  • Peter Gordon WebseCompany Secretary

Comunicados recentes

O que a Race Oncology (RAC) comunicou ao mercado, do mais recente para o mais antigo.

  1. EMILI Investor Webinar Nov 2026
  2. Sheba Grants Ethics Approval for EMILI AML TrialFato relevante
  3. Racura Successfully PK Bridges RC110 RC220Fato relevante
  4. Racura Presents Bisantrene MYC Data at FCS 2026
  5. Letter to Shareholders, Notice of AGM & Proxy Form
  6. Sept 2026 Quarterly Activities Report and Appendix 4CFato relevante
  7. HARNESS-1 First Cohort ClearedFato relevante
  8. Racura Presents CPACS Data at GCOS 2026

Principais indicadores financeiros

Resultados divulgados pela Race Oncology, em AUD.

Cap. de mercado
310,8 mi
Receita (TTM)
2,8 mi
P/L
—
LPA (diluído, TTM)
-0.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Race Oncology
Fim do ano fiscalReceitaResultado operacionalLucro líquido
—-12,4 mi-11,1 mi
6 mi-3,8 mi-4,8 mi
4 mi-17,8 mi-13,8 mi
3,1 mi-13 mi-9,9 mi